Mikrobiomik
Patricia del Rio's work experience is summarized as follows:
- Director of Business Development and Innovation at Mikrobiomik since May 2023 (present)
- Director of Clinical Research and Innovation at Mikrobiomik from September 2021 to May 2023
- Project Manager at Q² Solutions from November 2020 to September 2021
- Associate Director R&D at EnteroBiotix from November 2018 to August 2020
- Project Manager at Synpromics Ltd from January 2016 to September 2018
- Senior Scientist at Synpromics Ltd from July 2015 to December 2015
- Senior Research Associate at University of Glasgow from January 2014 to July 2015
- Postdoctoral researcher at Fundacion Inbiomed from 2011 to 2013
- PhD Student at Helmholtz zentrum Muenchen from 2006 to 2011
- Master student at UPV from June 2005 to September 2006
Patricia del Rio obtained a Doctor of Philosophy (Ph.D.) degree from Universidad del País Vasco/Euskal Herriko Unibertsitatea. Patricia also has several certifications, including the Good Clinical Practice (GCP) and Introduction to Clinical Trials certificate from JoBurmester.com, the Good Manufacturing Practice training certificate (GMP) from CARMODY CONSULTANCY LTD, and the MS Project Training Certificate from Pitman Training Group Ltd. Additionally, they have obtained certifications in Creative Thinking and Writing in Plain English from LinkedIn. In 2015, Patricia obtained a CMI Level 5 award in Management and Leadership (QCF) from the Chartered Management Institute. Furthermore, they completed online courses in Programmed cell death from Coursera in August 2013 and Drugs and the Brain from Coursera in February 2013.
This person is not in any teams
Mikrobiomik
Mikrobiomik is a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome. Our vision We aspire to be the first company in the world to market a medicine based on faecal microbiota in the EU. To that end, we are holding talks with both the EMA (European Medicines Agency) and the AEMPS (Spanish Agency for Medicines and Health Products) with a view to establishing protocols on the regulatory requirements for securing an MAA (Marketing Authorization Application) via centralised procedure. Our values Mikrobiomik seeks to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome through excellence in its processes, empathising with chronic patients for whom no curative treatments are available, always from the perspective of networking with all stakeholders in the sector.